News
Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.
In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...
The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback